Clinical trials: Somatostatin Receptor Positive
Breast Cancer Stage IV
Study of Dotatate Imaging in Breast Cancer
This will be a Phase 2 clinical trial to assess somatostatin receptor (SSTR) expression in Stage IV estrogen receptor positive (ER+) breast cancer using Gallium-68 DOTATATE or Copper-64 DOTATATE PET/CT.
- Trial name
- NCT05880394
- Testing
- Gallium-68 DOTATATE, Copper-64 DOTATATE
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hoag Memorial Hospital Presbyterian
Neuroendocrine Tumors
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
This is an open-label, single-dose, single-arm, single-center imaging study using DOTATATE peptide, labelled with the 64Cu tracer.
- Trial name
- NCT03673943
- Testing
- 64Cu-DOTATATE
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Radiomedix, Inc.